Searchable abstracts of presentations at key conferences in endocrinology

ea0034p422 | Thyroid | SFEBES2014

Neutrophil phagocytic capacity is lower in patients with abnormal thyroid function in critical illness

Browne Emma , Simpson John , Razvi Salman

Background: Thyroid function is affected by critical illness – termed as non-thyroidal illness – and usually presents with low serum TSH and FT3 levels but normal FT3 concentrations. Critically ill patients may also have impaired immune function that could contribute to increased susceptibility to acquired infections and mortality. Thyroid hormones influence neutrophil levels and function but the effect of non-thyroidal illness on neutrophil fun...

ea0013p76 | Clinical practice/governance and case reports | SFEBES2007

Acute falciparum malaria and parathyroid function

Pal Aparna , Karavitaki Niki , Wass John , Simpson Hugh

We present a rare case of acute falciparum malaria complicated by hypocalcaemia while having normal renal function.Case: A 64 year old African lady presented with a 2 week history of lethargy, weakness and oliguria. She had returned from Malawi a fortnight previously and had not taken antimalarial prophylaxis. Her malaria screen was positive for Plasmodium falciparum and she was commenced on quinine. On day 5 of her admission she developed perioral pares...

ea0038oc5.3 | Thyroid and parathyroid | SFEBES2015

Use of 11C-methionine PET to localise parathyroid adenoma/hyperplasia: a single centre experience

Challis Ben , Saad Ziauddin , Cheow H K , Buscombe John , Simpson Helen

Introduction: It is established practice to localise parathyroid lesions preoperatively using ultrasound (US) and sestaMIBI (MIBI). Whilst these imaging techniques have good sensitivity/specify, there are patients in which imaging does not localise a parathyroid lesion. 11C-Methionine PET (MET PET) is an imaging modality where 11C-methionine, a radioactive tracer, is taken up at sites of protein/peptide synthesis and has been demonstrated to be effective ...

ea0044p135 | Neoplasia, cancer and late effects | SFEBES2016

The effect of peptide receptor radionuclide therapy (PRRT) on symptoms and tumour burden in patients with metastatic neuroendocrine tumour (NET)

Abraham Stalin , Casey Ruth , Challis Ben , Pitfield Deborah , Whitley S , Shaw Ashley , Heard Sarah , Saad Zia , Buscombe John , Simpson Helen

Peptide receptor radionuclide therapy (PRRT) is a targeted therapy using synthetic somatostatin analogues attached to a radionuclide, which binds to tumours expressing somatostatin receptors. The aim was to review the role of PRRT in a tertiary referral centre. We retrospectively reviewed a cohort of 25 patients (eight males, 17 females), with a median age of 65, who received Yttrium-90 DOTATATE or Lutetium-177 DOTATATE at Addenbrookes Hospital. The location of the primary tum...